EVALUATION OF ANTIHYPERTENSIVE DRUG USE ON THERAPY OUTCOMES IN CHRONIC KIDNEY DISEASE (CKD) PATIENTS AT RSUD BENDAN PEKALONGAN

Abstract

Chronic Kidney Disease (CKD) is a progressive and irreversible condition with hypertension as a major contributing factor. Proper management of blood pressure is essential to prevent worsening renal function and improve patient outcomes. This study aimed to evaluate the use of antihypertensive drugs and their impact on therapy outcomes (Blood pressure, GFR, and QoL) in CKD patients at RSUD Bendan Pekalongan. This research employed a prospective observational method and involved 50 CKD outpatients receiving antihypertensive therapy. Data were collected over a two-month period through clinical measurements and patient-reported outcomes. Blood pressure, GFR and QoL were assessed before and after treatment. QoL was measured using the KDQOL-36 questionnaire. Data were analyzed using univariate and bivariate methods, including paired t-tests. The results showed that 96% of patients received combination therapy, most commonly involving diuretics, calcium channel blockers (CCB), and angiotensin receptor blockers (ARB). Average blood pressure decreased from 146/92 mmHg to 128/83 mmHg, GFR increased from 5.96 to 6.70 mL/min, and QoL scores improved from 288 to 348. These changes were statistically significant. In conclusion, antihypertensive therapy in CKD patients was effective in improving clinical outcomes, including blood pressure control, kidney function, and quality of life. The findings support the implementation of combination therapy as a standard approach in managing hypertension among CKD patients